BRAIN Biotech AG (XTER:BNN) EV-to-EBIT : -7.94 (As of Jun. 19, 2024)

BRAIN Biotech AG EV-to-EBIT Chart

BRAIN Biotech AG Annual Data
	Trend	Sep15	Sep16	Sep17	Sep18	Sep19	Sep20	Sep21	Sep22	Sep23
EV-to-EBIT		Get a 7-Day Free Trial				-19.43	-13.73	-53.13	-18.16	-14.04

BRAIN Biotech AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-18.35	-15.88	-14.04	-12.16	-11.43

Competitive Comparison of BRAIN Biotech AG's EV-to-EBIT

For the Specialty Chemicals subindustry, BRAIN Biotech AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BRAIN Biotech AG's EV-to-EBIT Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's EV-to-EBIT falls into.

BRAIN Biotech AG EV-to-EBIT Calculation

BRAIN Biotech AG's EV-to-EBIT for today is calculated as:

BRAIN Biotech AG's current Enterprise Value is €48.98 Mil.
BRAIN Biotech AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG  (XTER:BNN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BRAIN Biotech AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

BRAIN Biotech AG's Enterprise Value for the quarter that ended in Mar. 2024 was €70.50 Mil.
BRAIN Biotech AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BRAIN Biotech AG (XTER:BNN) Business Description